Results 101 to 110 of about 16,378 (224)

Double-negative neuromyelitis optica spectrum disorder

open access: hybrid, 2023
Yan Wu   +3 more
openalex   +1 more source

Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system [PDF]

open access: yes, 2018
Background: Diffusion Tensor Imaging (DTI) can evaluate microstructural tissue damage in the optic radiation (OR) of patients with clinically isolated syndrome (CIS), early relapsing-remitting multiple sclerosis and neuromyelitis optica spectrum ...
Backner, Yael   +9 more
core   +2 more sources

Study of the cytological features of bone marrow mesenchymal stem cells from patients with neuromyelitis optica. [PDF]

open access: yes, 2019
Neuromyelitis optica (NMO) is a refractory autoimmune inflammatory disease of the central nervous system without an effective cure. Autologous bone marrow‑derived mesenchymal stem cells (BM‑MSCs) are considered to be promising therapeutic agents for this
Chang, Guoqiang   +6 more
core   +1 more source

A Perspective of Coagulation Dysfunction in Multiple Sclerosis and in Experimental Allergic Encephalomyelitis [PDF]

open access: yes, 2018
A key role of both coagulation and vascular thrombosis has been reported since the first descriptions of multiple sclerosis (MS). Subsequently, the observation of a close concordance between perivascular fibrin(ogen) deposition and the occurrence of ...
Adams   +158 more
core   +1 more source

Immunoadsorption in patients with neuromyelitis optica spectrum disorder

open access: yesTherapeutic Advances in Neurological Disorders, 2016
Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a neuroinflammatory disorder of the central nervous system, distinct from multiple sclerosis by affecting predominantly the optic nerve and the spinal cord, and mediated by antibodies ...
Simon Faissner   +5 more
doaj   +1 more source

Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report

open access: yesBMC Cancer, 2018
Background Immune checkpoint blockade is developed as standard treatment for non-small cell lung cancer. However immune-related adverse events (irAE) have still unknown complications.
Yoshitsugu Narumi   +12 more
doaj   +1 more source

Tumefactive Demyelination in MOG Ab–Associated Disease, Multiple Sclerosis, and AQP-4-IgG–Positive Neuromyelitis Optica Spectrum Disorder [PDF]

open access: green, 2023
Laura Cacciaguerra   +17 more
openalex   +1 more source

Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic [PDF]

open access: bronze, 2020
Hesham Abboud   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy